LEVELS OF MIDDLE MOLECULAR PEPTIDES IN THE KIDNEYSOF RATS WITH HYPERHOMOCYSTEINEMIA
DOI:
https://doi.org/10.17721/1728.2748.2026.105.49-54Keywords:
hyperhomocysteinemia, kidneys, middle molecular peptidesAbstract
Background. Chronic kidney disease (CKD) is a global health care problem, with the majority of cases occurring in stage 3. Since the disease can progress insidiously, early diagnosis is crucial for timely intervention. One of the risk factors for the development of CKD is hyperhomocysteinemia. The detection of atypical medium-molecular peptides in kidney homogenate may be an important component of this condition. The aim of the study was to determine the level of middle molecular peptides in kidney homogenate of adult and immature rats with hyperhomocysteinemia.
Methods. The experiments were conducted on white male non-linear rats which maintained on a standard vivarium diet.The model of hyperhomocysteinemia was reproduced on one- and six-month-old male rats, which were kept on a standard vivarium diet. The experimental group was intragastrically administered by D,L-thiolactone homocysteine hydrochloride in a 1 % starch solution at a dose of 200 mg/kg of body weight 1 per day for 8 weeks. The corresponding volume of 1 % starch solution was injected into the control group of animals. The protein concentration was determined by the Bradford method. The concentration of middle-molecular peptide fractions was determined at wavelengths of 210, 238 and 254 nm.
Results. It was shown that in the kidneys of immature and adult rats with hyperhomocysteinemia, an increase in the level of middle-molecular peptides occurs. The most significant changes were established for the indicators determined at a wavelength of 210 nm in the group of animals with hyperhomocysteinemia.
Сonclusions. The results obtained indicate metabolic disorders in the body of rats with hyperhomocysteinemia. The established differences in the quantitative composition of the obtained fractions of kidney homogenate may be the basis for further studies on the identification of individual peptides as markers of the development and progression of Chronic kidney disease in hyperhomocysteinemia.
Downloads
References
Badri, S., Vahdat, S., Seirafian, S., Pourfarzam, M., Gholipur-Shahraki, T., & Ataei, S. (2021). Homocysteine-Lowering Interventions in Chronic Kidney Disease. Journal of research in pharmacy practice, 10(3), 114–124. https://doi.org/10.4103/jrpp.jrpp_75_21
Behera, J., Bala, J., Nuru, M., Tyagi, S. C., & Tyagi, N. (2017). Homocysteine as a Pathological Biomarker for Bone Disease. Journal of cellular physiology, 232(10), 2704–2709. https://doi.org/10.1002/jcp.25693
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248–254. https://doi.org/ 10.1016/0003-2697(76)90527-3
Chen, W., Feng, J., Ji, P., Liu, Y., Wan, H., & Zhang, J. (2023). Association of hyperhomocysteinemia and chronic kidney disease in the general population: a systematic review and meta-analysis. BMC nephrology, 24(1), 247. https://doi.org/10.1186/s12882-023-03295-y
Ding, C. C., Huang, X., Bao, H. H., & Cheng, X. S. (2025). Research Progress in the Relationship Between Hyperhomocysteinemia and Chronic Kidney Disease. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 47(2), 281–288. https://doi.org/10.3881/j.issn.1000-503X.16112
Jan, M., Cueto, R., Jiang, X., Lu, L., Sardy, J., Xiong, X., Yu, J. E., Pham, H., Khan, M., Qin, X., Ji, Y., Yang, X. F., & Wang, H. (2021). Molecular processes mediating hyperhomocysteinemia-induced metabolic reprogramming, redox regulation and growth inhibition in endothelial cells. Redox biology, 45, 102018. https://doi.org/10.1016/j.redox.2021.102018
Koval, Т., Savchuk, О., & Raksha, N. (2025). Content of middle molecular peptides in the tissues of rats with alkali burns of the esophagus. Bulletin of Taras Shevchenko National University of Kyiv. Biology, 103(4), 28–34 [in Ukrainian]. https://doi.org/10.17721/1728.2748.2025.103.28-34
Kuchma, I. L. (2021). Uremic toxins. Back to the future. Kidneys, 10(2), 43–52 [in Ukrainian]. https://doi.org/10.22141/2307-1257.10.2.2021.234323
Liu, C., Lin, L., & Xu, R. (2020). Elevated homocysteine and differential risks of the renal function decline in hypertensive patients. Clinical and experimental hypertension (New York, N.Y. : 1993), 42(6), 565–570. https://doi.org/10.1080/10641963.2020.1739698
Liu, P. T., & Chen, J. D. (2021). Synergistic association of hyperuricemia and hyperhomocysteinemia with chronic kidney disease in middle-aged adults and the elderly population. Medicine, 100(37), e27202. https://doi.org/10.1097/MD.0000000000027202
Lykhatskyi, P. H., Fira, V. D., Fira, L. S., & Boyko, L. A. (2022). Development of endogenic intoxication in rats under nitrite tobacco toxicosis after carboline application. Bulletin of Medical and Biological Research, 4(1), 57–63. https://doi.org/10.11603/bmbr.2706-6290.2022.1.12971
National Kidney Foundation. (2024). Kidney Disease: Fact Sheet. https:// www.kidney.org/about/kidney-disease-fact-sheet#fast-facts-2024-update
Perna, A. F., Zacchia, M., Trepiccione, F., & Ingrosso, D. (2017). The Sulfur Metabolite Lanthionine: Evidence for a Role as a Novel Uremic Toxin. Toxins, 9(1), 26. https://doi.org/10.3390/toxins9010026
Raksha, N., Maievskyi, O., Dzevulska, I., Kaminsky, R., Samborska, I., Savchuk, O., & Kovalchuk, О. (2022). Proteolytic activity in the heart of rats with hyperhomocysteinemia. Wiadomosci lekarskie (Warsaw, Poland : 1960), 75(4 pt 1), 831–835. https://doi.org/10.36740/WLek202204115
Rosner, M. H., Reis, T., Husain-Syed, F., Vanholder, R., Hutchison, C., Stenvinkel, P., Blankestijn, P.J., Cozzolino, M., Juillard, L., Kashani, K., Kaushik, M., Kawanishi, H., Massy, Z., Sirich, T. L., Zuo, L., & Ronco, C. (2021). Classification of Uremic Toxins and Their Role in Kidney Failure. Clinical journal of the American Society of Nephrology: CJASN, 16(12), 1918–1928. https://doi.org/10.2215/CJN.02660221
Savchuk, O., Korotkyi, О., & Коt, L. (2021). Level of middle molecular peptides in the articular cartilage of rats under experimental osteoarthritis and administration of probiotic composition. Bulletin of Taras Shevchenko National University of Kyiv. Biology, 87(4), 38–44. https://doi.org/10.17721/ 1728.2748.2021.87.38-44
Serbin, А., Strelkova, К., Koval, Т., Kharchenko, О., & Andriichuk, Т. (2022). Research of indicators of oxidative stress in the kidneys of immature rats with hyperhomocysteinemia. Bulletin of Taras Shevchenko National University of Kyiv. Biology, 91(4), 5–9 [in Ukrainian]. https://doi.org/ 10.17721/1728.2748.2022.91.5-9
Skovierova, H., Vidomanova, E., Mahmood, S., Sopkova, J., Drgova, A., Cervenova, T., Halasova, E., & Lehotsky, J. (2016). The Molecular and Cellular Effect of Homocysteine Metabolism Imbalance on Human Health. International journal of molecular sciences, 17(10), 1733. https://doi.org/ 10.3390/ijms17101733
Smith, A. D., & Refsum, H. (2021). Homocysteine – from disease biomarker to disease prevention. Journal of internal medicine, 290(4), 826–854. https://doi.org/10.1111/joim.13279
Song, Z., Tsou, S., Martin, F., Kayumov, M., Xiao, Y., Zhou, H., Abdi, R., & Tullius, S. G. (2026). Kidney Disease as a Driver of Immunosenescence: Mechanisms and Potential Interventions. Journal of the American Society of Nephrology : JASN, 37(2), 405–416. https://doi.org/10.1681/ASN.0000000896
Steed, M. M., & Tyagi, S. C. (2011). Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxidants & redox signaling, 15(7), 1927–1943. https://doi.org/10.1089/ars.2010.3721
The European Work Group on Uremic toxins. (2020). Uremic Solutes Database https://database.uremic-toxins.org/soluteList.php
Vanholder, R., Argilés, A., Jankowski, J., & European Uraemic Toxin Work Group (EUTox). (2021). A history of uraemic toxicity and of the European Uraemic Toxin Work Group (EUTox). Clinical kidney journal, 14(6), 1514–1523. https://doi.org/10.1093/ckj/sfab011
Vanholder, R., Pletinck, A., Schepers, E., & Glorieux, G. (2018). Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. Toxins, 10(1), 33. https://doi.org/10.3390/ toxins10010033
Wu, K., Liu, K., Xie, L., Lu, G., Ma, S., Li, G., Cao, J., Jie, Y., Jiang, Y., & Hao, Y. (2021). Mechanism of hyperhomocysteinemia induced renal injury in Cbs+/- mice[J]. Chinese Journal of Tissue Engineering Research, 25(11), 1728–1732. https://doi.org/10.3969/j.issn.2095-4344.3084
Yi, M., Ma, Y., Zhu, S., Luo, C., Chen, Y., Wang, Q., & Deng, H. (2020). Comparative proteomic analysis identifies biomarkers for renal aging. Aging, 12(21), 21890–21903. https://doi.org/10.18632/aging.104007
Zaric, B. L., Obradovic, M., Bajic, V., Haidara, M. A., Jovanovic, M., & Isenovic, E. R. (2019). Homocysteine and Hyperhomocysteinaemia. Current medicinal chemistry, 26(16), 2948–2961. https://doi.org/10.2174/ 0929867325666180313105949
Zhang, J., Zhang, D., Xu, Z., Wang, Y., & Qin, X. (2025). Progress in the Mechanism of Hyperhomocysteinemia-Induced Renal Injury. Clinical laboratory, 71(12), 10.7754/Clin.Lab.2025.250335. https://doi.org/10.7754/ Clin.Lab.2025.250335
